GLP1 Analogues and the Risk of Osteoarthritis

NCT07360457 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 390

Last updated 2026-01-22

No results posted yet for this study

Summary

Assessing the effects of GLP1 RA Vs SGLT2 Inhibitors vs. Standard of care in joint pain, physical function, stiffness, and improving Quality of Life for patients with type 2 diabetes.

Conditions

Interventions

DRUG

GLP-1 analog

glucagon like peptide analogues

DRUG

SGLT2 inhibitor

sodium glucose transporter-2 inhibitors

DRUG

Antidiabetic

Standard of care

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Asmaa Elsayed · Sohag University

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2026-12-01
Completion
2027-03-01

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07360457 on ClinicalTrials.gov